PROMIS NEUROSCIENCES INC. Proceeds from Convertible Debt
PROMIS NEUROSCIENCES INC. (PMN) reported Proceeds from Convertible Debt of $6.92 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2023-03-08
- PROMIS NEUROSCIENCES INC. proceeds from convertible debt for the quarter ending 2021-12-31 was $0.00.
- PROMIS NEUROSCIENCES INC. proceeds from convertible debt for the quarter ending 2021-09-30 was $32.67K.
- PROMIS NEUROSCIENCES INC. proceeds from convertible debt for fiscal 2021 was $6.92M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $32.67K derived: sum of 2 quarters · filed 2023-03-08 | $6.92M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $32.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.92M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $6.88M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |